Background : to evaluate the response rate , survival and safety of the combination of temozolamide and whole brain radiotherapy in breast cancer patients with previously untreated brain metastases Patients and Methods:40 patients with brain metastases were divided in two groups Control arm(A): patients received whole brain radiotherapy(WBRT) at a dose of 30 Gy in 10 daily fractions over 2 weeks. TMZ plus WBI arm (B): patients treated with (WBRT) at a dose of 30 Gy in 10 daily fractions over 2 weeks concomitant with temozolamide. The primary endpoint was overall response (OR) Secondary endpoints were progression free survival (PFS) and overall survival ( OS) Results: Patients who received WBI and TMZ had an overall response of 45% compared with 40% in WBI alone with no statistically significant difference. Brain metastasis progression was observed in 45% in the control group(A) versus 15% in group B with a statistically significant difference (p=0.038) . Median progression free survival ( PFS) was 6 months in group A but 9.5 in group B with non significant difference. One year progression free survival was 37.5% in group A versus 45% in group B . One year overall survival was 33.3% in group A versus 47.8% in group B . Median overall survival was 7 months in group A versus 11 months in group B with non-significant difference. Most of patients had tolerable side effects and recovered eventually. Conclusion: Although, the combination of WBRT and TMZ was safe and appeared to improve local control , OS and PFS of BMs from breast cancer in this study, this improvement was non- significant, and further studies with larger number of patients are needed to get significant results.